Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017.SR)
Jeddah, SA
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50% | -1.16% | +3.46% | +4.60% | -8.23% | +5.34% | -20.35% | -37.53% | -37.53% | -37.53% | -37.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+10.7% ★ Q1'26: +3.3% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-4.6% Q1'26: -45.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+6.0% Q1'26: +9.8% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+9.5% Q1'26: +5.6% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+6.0% Q1'26: +2.8% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+5.9% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×4.01× Q1'26: 7.83× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
2.79B
est: 2.83B (-1.4%)
|
3.09B
est: 3.10B (-0.5%)
|
3.41B
3.39B – 3.43B
+9.7% YoY
|
4.02B
3.94B – 4.09B
+18.1% YoY
|
4.68B
4.61B – 4.73B
+16.3% YoY
|
5.61B
5.53B – 5.67B
+19.9% YoY
|
6.16B
6.07B – 6.23B
+9.8% YoY
|
| EBITDA |
545.62M
est: 545.47M (+0.0%)
|
293.10M
est: 598.23M (-51.0%)
|
656.38M
652.27M – 660.50M
+9.7% YoY
|
775.04M
759.70M – 787.14M
+18.1% YoY
|
901.20M
888.88M – 911.46M
+16.3% YoY
|
1.08B
1.07B – 1.09B
+19.9% YoY
|
1.19B
1.17B – 1.20B
+9.8% YoY
|
| EBIT |
382.74M
est: 439.03M (-12.8%)
|
293.10M
est: 481.50M (-39.1%)
|
528.30M
524.99M – 531.61M
+9.7% YoY
|
623.80M
611.45M – 633.54M
+18.1% YoY
|
725.34M
715.43M – 733.60M
+16.3% YoY
|
870.00M
858.10M – 879.90M
+19.9% YoY
|
954.98M
941.92M – 965.85M
+9.8% YoY
|
| Net Income |
287.55M
est: 317.49M (-9.4%)
|
290.20M
est: 287.55M (+0.9%)
|
290.57M
283.16M – 297.99M
+1.1% YoY
|
360.35M
357.66M – 363.53M
+24.0% YoY
|
370.31M
363.73M – 375.79M
+2.8% YoY
|
347.31M
341.14M – 352.45M
-6.2% YoY
|
494.52M
485.72M – 501.83M
+42.4% YoY
|
| SGA |
337.69M
est: 336.13M (+0.5%)
|
404.70M
est: 368.65M (+9.8%)
|
404.49M
401.95M – 407.02M
+9.7% YoY
|
477.61M
468.15M – 485.06M
+18.1% YoY
|
555.35M
547.76M – 561.67M
+16.3% YoY
|
666.10M
657.00M – 673.69M
+19.9% YoY
|
731.17M
721.17M – 739.50M
+9.8% YoY
|
| EPS |
1.32
est: 1.38 (-4.4%)
|
1.26
est: 1.25 (+0.8%)
|
1.26
1.23 – 1.30
+1.1% YoY
|
1.57
1.56 – 1.58
+24.0% YoY
|
1.61
1.58 – 1.63
+2.8% YoY
|
1.51
1.48 – 1.53
-6.2% YoY
|
2.15
2.11 – 2.18
+42.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-03 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-26 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-19 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.21% | 1.33M | 0.75% |
| 2 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 108.0K | 0.74% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 105.2K | 0.72% |
| 4 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 76.4K | 0.55% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 36.3K | 0.56% |
| 6 | State Street SPDR Morningstar Multi-Asset Global Infrastructure UCITS ETF (Dist) MAGI.L | 0.01% | 89.0K | 0.40% |
| 7 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.01% | 15.1K | 0.07% |
| 8 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 86.3K | 0.18% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 2.10M | 0.18% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 6.96M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mazen Soliman Abdel Kader Fakeeh | MD, Group President & Director, Marketing & Business Development Director | 158.0K | — |
| Ayman Asaad Soliman Abdo | Group Senior Vice President & Executive Director | 156.0K | — |
| Ibrahim Nusrat Hayat | Group Chief Revenue Cycle Officer | — | — |
| Khadra Mohamed Omar | Chief Nursing Officer | — | female |
| Othman Abdulmuti Amin | Group Internal Audit Acting Chief Executive Officer | — | — |
| Panagiotis Chatziantoniou | Group Chief Financial Officer | — | male |
| Samar Assem Badreddine | President of Quality Standards & Compliance | — | — |
| Steven Green | Chief of Hospitality Division | — | male |
| Taimoor Ali Soomro | Chief Financial Officer | — | male |
| Anas Shaban Banah | Chief Medical & Clinical Officer | — | — |
| Tamer Said Abdelgawad | Group Vice President of Operations | — | male |
| Barbara Allison | Executive Director of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4017.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
